Fred D. Lublin, MD

home / authors / fred-d-lublin-md

Saunders Family Professor of Neurology, and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai

Articles

Classification and Diagnosis of SPMS

Classification and Diagnosis of SPMS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD
March 24th 2021

Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.

Diagnosing SPMS

Diagnosing SPMS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD
March 18th 2021

An overview of the criteria used to diagnose relapsing-remitting multiple sclerosis when it converts to secondary progressive multiple sclerosis.

Clinical Subtypes of MS

Clinical Subtypes of MS

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD
March 18th 2021

A panel of experts led by Bruce Cree, MD, highlight the clinical subtypes of multiple sclerosis including presentation and prevalence.

The Future of Treating Multiple Sclerosis

The Future of Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Decision-Making Process for Treating Multiple Sclerosis

Decision-Making Process for Treating Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Switching Therapies in Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ozanimod in Multiple Sclerosis

Role of Ozanimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Diroximel Fumarate in Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Ocrelizumab in Europe for Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Ocrelizumab for the Treatment of Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Role of Siponimod in Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Treating With Cladribine in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinical Trials for Cladribine in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Glatiramer Acetate in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
The Use of Interferon in Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
First-Line Therapies for Relapsing Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Clinically Isolated Syndrome Versus Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
MOG-IgG in Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Differential Diagnosis of Multiple Sclerosis

Differential Diagnosis of Multiple Sclerosis

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
Diagnosis of Multiple Sclerosis: The McDonald Criteria

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Sven Meuth, MD, PhD;Patricia Coyle, MD;Wallace Brownlee, MBChB, PhD, FRACP;Fred D. Lublin, MD
September 3rd 2020
<12

Latest Updated Articles

Robert A. Hauser, MD, MBA (Credit: USF Health)
Published: October 17th 2024 | Updated: October 21st 2024
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment
Jacob McCauley, PhD (Credit: Miami Miller School of Medicine)
Published: September 18th 2024 | Updated: September 20th 2024
Multi-Ethnic Study Identifies Ancestry-Specific Genetic Variants that Influence Risk of Multiple Sclerosis
Todd Sherer, PhD (Credit: The Michael J. Fox Foundation for Parkinson's Research)
Published: September 9th 2024 | Updated: September 11th 2024
FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Lee Golden, MD (Credit: PTC Therapeutics)
Published: August 24th 2024 | Updated: August 26th 2024
Vatiquinone Pharmacokinetics Influenced by CYP3A4 Inhibitors and Inducers in Phase 1 Study
Renaud Du Pasquier, MD (Credit: University of Lausanne)
Published: August 22nd 2024 | Updated: August 23rd 2024
Novel Cell-Based Assay Enhances Detection of Autoantibodies in Neurological Disorders
Anna Castagna, MD
Published: August 6th 2024 | Updated: August 15th 2024
The Need for Flexibility and Patient-Centered Approaches in Clinical Trials for Cervical Dystonia: Anna Castagna, MD
© 2024 MJH Life Sciences

All rights reserved.